| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
Bayogenin targets multiple pathways. It inhibits glycogen phosphorylase, an enzyme involved in glycogen breakdown, with moderate potency (IC₅₀ = 68 µM). Its anti-inflammatory activity is mediated through the inhibition of inflammatory mediators. Its anticancer activity is attributed to its ability to induce apoptosis in tumor cells. It also modulates immune responses. Its multi-targeted activity makes it a compound of interest for studying inflammation, cancer, and metabolic diseases.
|
|---|---|
| ln Vitro |
In vitro, Bayogenin has been shown to inhibit glycogen phosphorylase (IC₅₀ = 68 µM). It exhibits anti-inflammatory, antimicrobial, and anticancer activities. Its ability to inhibit inflammatory mediators and induce apoptosis in tumor cells has been demonstrated in various cell-based assays.
|
| ln Vivo |
In vivo, Bayogenin's anti-inflammatory and anticancer activities suggest potential therapeutic applications. Its ability to modulate immune responses could be beneficial in autoimmune diseases. However, specific in vivo data are not detailed in the provided search results.
|
| Enzyme Assay |
In vitro non-cell enzyme assays for Bayogenin involve measuring its inhibition of glycogen phosphorylase activity. The enzyme is incubated with the compound, its substrate glycogen, and the cofactor. The production of glucose-1-phosphate is measured, and the IC₅₀ is determined from dose-response curves.
|
| Cell Assay |
In vitro cell-based assays for Bayogenin use various cell lines to study its anti-inflammatory, antimicrobial, and anticancer activities. For anti-inflammatory studies, macrophages are stimulated with LPS, and the production of inflammatory cytokines is measured. For anticancer studies, cancer cell lines are treated with the compound, and cell viability, apoptosis, and proliferation are assessed.
|
| Animal Protocol |
In vivo animal studies for Bayogenin would likely employ models of inflammation and cancer. For anti-inflammatory studies, models such as carrageenan-induced paw edema would be used. For anticancer studies, xenograft models would be used. The compound would be administered, and its effects on inflammation, tumor growth, and immune response would be assessed.
|
| ADME/Pharmacokinetics |
Bayogenin has a molecular weight of 488.70 g/mol and a molecular formula of C₃₀H₄₈O₅. It is a pentacyclic triterpenoid aglycone. It has a purity of >98%. It appears as a powder. The compound should be stored under appropriate conditions, typically at -20°C, protected from light and moisture.
|
| Toxicity/Toxicokinetics |
The toxicity profile of Bayogenin is not extensively detailed. As a natural product from alfalfa and horse chestnut, it is generally considered to have a good safety profile. However, comprehensive toxicological studies are required for therapeutic development. It is not intended for human therapeutic use without further development.
|
| References |
|
| Additional Infomation |
Bayogenin is a pentacyclic triterpenoid compound derived from the hydride of oleanane. It has been reported to exist in dodecyl podophyllum, Sinomenium acutum, and other organisms with relevant data.
Bayogenin is a pentacyclic triterpenoid aglycone with anti-inflammatory, antimicrobial, and anticancer activities. It inhibits glycogen phosphorylase (IC₅₀ = 68 µM). It is found in alfalfa and horse chestnut. It is not approved for clinical use and is intended for research purposes only. |
| Molecular Formula |
C30H48O5
|
|---|---|
| Molecular Weight |
488.6991
|
| Exact Mass |
488.35
|
| CAS # |
6989-24-8
|
| PubChem CID |
12305221
|
| Appearance |
White to off-white solid powder
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
606.0±55.0 °C at 760 mmHg
|
| Flash Point |
334.3±28.0 °C
|
| Vapour Pressure |
0.0±3.9 mmHg at 25°C
|
| Index of Refraction |
1.581
|
| Source |
Originated from plants: Cucurbitaceae Bolbostemma paniculaum (Maxim)Franguet
|
| LogP |
6.51
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
35
|
| Complexity |
941
|
| Defined Atom Stereocenter Count |
10
|
| SMILES |
C[C@@]12CC[C@@H]3[C@@]([C@H]1CC=C4[C@]2(CC[C@@]5([C@H]4CC(CC5)(C)C)C(=O)O)C)(C[C@@H]([C@@H]([C@@]3(C)CO)O)O)C
|
| InChi Key |
RWNHLTKFBKYDOJ-JEERONPWSA-N
|
| InChi Code |
InChI=1S/C30H48O5/c1-25(2)11-13-30(24(34)35)14-12-28(5)18(19(30)15-25)7-8-22-26(3)16-20(32)23(33)27(4,17-31)21(26)9-10-29(22,28)6/h7,19-23,31-33H,8-17H2,1-6H3,(H,34,35)/t19-,20-,21+,22+,23-,26-,27-,28+,29+,30-/m0/s1
|
| Chemical Name |
(4aS,6aR,6aS,6bR,8aR,9R,10R,11S,12aR,14bS)-10,11-dihydroxy-9-(hydroxymethyl)-2,2,6a,6b,9,12a-hexamethyl-1,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-4a-carboxylic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~33.33 mg/mL (~68.20 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (5.12 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (5.12 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.0462 mL | 10.2312 mL | 20.4625 mL | |
| 5 mM | 0.4092 mL | 2.0462 mL | 4.0925 mL | |
| 10 mM | 0.2046 mL | 1.0231 mL | 2.0462 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
